
Ibudilast - Wikipedia
Ibudilast (development codes: AV-411 or MN-166) is an anti-inflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE4 subtype to the greatest extent, [1] but also showing significant inhibition of other PDE subtypes.
Ibudilast: Uses, Interactions, Mechanism of Action - DrugBank …
2007年11月18日 · Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS).
Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast …
Ibudilast, an anti-inflammatory drug firstly developed as an asthma treatment, is a cyclic nucleotide phosphodiesterases (PDEs) inhibitor, which mainly acts by increasing the amount of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), while downregulating the pro-inflammatory factors, such as tumor necrosis factor-...
Ibudilast, a neuroimmune modulator, reduces heavy drinking …
2021年6月12日 · Ibudilast, a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE)-3, -4, -10, and -11, and macrophage migration inhibitory factor (MIF), shows promise as a novel...
Ibudilast: a review of its pharmacology, efficacy and safety in ...
Ibudilast is a relatively nonselective phosphodiesterase inhibitor which has been marketed for almost 20 years in Japan for treating asthma. More recently it has been found to have anti-inflammatory activity in both the peripheral immune system and in …
Ibudilast | C14H18N2O | CID 3671 - PubChem
Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS).
Ibudilast (KC-404,异丁司特) - 仅供科研 | 磷酸二酯酶抑制剂 | MCE
Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility.
Ibudilast - an overview | ScienceDirect Topics
Ibudilast (MN-166) is an anti-inflammatory and neuroprotective oral agent, and a first-in-class, small molecule inhibitor of phosphodiesterase-4 and -10, as well as macrophage migration inhibitory factor (MIF).
Ibudilast
Clinical and preclinical findings indicate that the drug Ibudilast can stimulate neuroprotective and regenerative processes in the spinal cord. Ibudilast is well-tolerated and used to treat asthma and post-stroke dizziness in Japan and is currently being investigated for use in treating other neurological diseases.
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
2018年8月29日 · Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood–brain barrier, with potential...
- 某些结果已被删除